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Abstract 
 
BACKGROND: Tight glycemic control (TGC) in critical care has shown distinct 
benefits but also been proven to be difficult to obtain. The risk of severe 
hypoglycemia (< 40 mg/dL) has been significantly increased in several, but not all, 
studies, raising significant concerns for safety. Continuous glucose monitors (CGMs) 
offer frequent measurement and thus the possibility of using them for early detection 
alarms to prevent hypoglycemia. 
 
METHODS: This study uses retrospective clinical data from the SPRINT TGC study 
covering 7 patients who experienced severe hypoglycemic events. Clinically 
validated metabolic system models are used to recreate a continuous blood glucose 
profile. In silico analysis is enabled by using a conservative single Gaussian noise 
model based on reported CGM clinical data from a critical care study (MAPE 17.4%). 
A novel median filter is implemented and further smoothed with a LMS fitted 
polynomial to reduce sensor noise. 
 
Two alarm approaches are compared. An integral based method is presented that 
examines the area between a pre-set threshold and the filtered simulated CGM data. 
An alarm is raised when this value becomes too low. A simple glycemic threshold 
method is also used for comparison.  
 
To account for random noise skewing the results, each patient record is Monte Carlo 
simulated 100 times with a different random noise profile for a total of 700 runs. 
Different alarm thresholds are analysed parametrically. Results are reported in terms 
of detection time before the clinically measured event, and any false alarms. This 
retrospective clinical data was used with approval from the NZ South Island Regional 
Ethics Committee. 
 
RESULTS: The median filter reduces MAPE from 17.4% (SD 13%) to 9.3% (SD 7%) 
over the cohort. For the integral based alarm, median per-patient detection times 
ranged, t, from -35 minutes (before event) to -170 minutes, with 0-2 false alarms per 
patient over the cohort and different alarm parameters. For a simple glycemic 
threshold alarm (3 consecutive values below threshold) median per-patient alarm 
times were -10 to -75 minutes, false alarms were 0 to 7, but in one case 5 of 7 
subjects never alarmed at all despite the hypoglycemic event. 
 
CONCLUSIONS: A retrospective study used clinical hypoglycemic events from a 
TGC study to develop and analyse an integral based hypoglycemia alarm for use in 
critical care TGC studies. The integral based approach was accurate, provided 
significant lead time before a hypoglycemic event, alarmed at higher glycemic levels, 
was robust to sensor noise, and had minimal false alarms. The approach is readily 
generalisable to similar scenarios and the results would justify a pilot clinical trial to 
verify this study. 
 
1.0 Introduction: 
 
Critically ill patients often experience stress-induced hyperglycemia and high levels of 
insulin resistance, even with no prior diabetes [1-7]. Hyperglycemia worsens 
outcomes, increasing the risk of severe infection [8], myocardial infarction [1], and 
critical illness such as polyneuropathy and multiple organ failure [7]. The occurrence 
of hyperglycemia, particularly severe hyperglycemia, is associated with increased 
morbidity and mortality in this group of patients [1, 3]. 
 
Some studies have shown that tight glucose control (TGC) reduced intensive care 
unit patient mortality by 45% following control limits of 110 to 140 mg/dL [7, 9-11]. 
However, there is a little agreement on what constitutes desirable glycemic 
performance [12-14], particularly with regard to how TGC affects outcome. Thus, 
despite the potential, many intensive care units do not used fixed protocols [4, 12, 
13, 15, 16].  
 
Overall, any glycemic control protocol must reduce elevated blood glucose levels 
with minimal hypoglycaemia. Thus, minimising risk in the presence of significant 
variability in insulin resistance resulting from conflicting drug therapies and 
dynamically evolving physiological condition among others. As patient condition 
evolves, particularly acutely, TGC and intensive insulin therapy can prove difficult. 
Protocols or clinical practises that utilize large insulin doses can thus suffer from high 
glycemic variability and excessive hypoglycemia [17]. As a result, several clinical 
trials have not achieved the benefit of TGC [17-20]. 
 
Hence, there is a significant difficulty in providing protocols that simultaneously 
provide good performance and TGC without excessive hypoglycemia. The two major  
reasons or causes of hypoglycemia are often reported to be clinical error and, or 
combined with, infrequent measurement using bedside glucometers or blood gas 
analysers [19, 21-24]. Thus, the use of continuous glucose monitors (CGMs) with 
their rapid 2-5 minute measurement rates offers the opportunity to better monitor 
patients so that hypoglycemia could be avoided, mitigating this risk significantly.  
 
Typically, in most ICU studies blood glucose is measured 1-4 hourly, faster only if the 
levels are already hypoglycemic. The result can be very variable glycemic control, 
especially with longer measurement intervals [25]. Thus, CGMs would also provide 
the potential to better or more tightly control glycemic levels minimising variability, 
which has also been strongly linked with mortality, independent of glycemic levels, in 
these cohorts [26, 27].  
 
However, there have been relatively few successful investigations of CGMs in critical 
care use [28], although they are well studied in Type 1 diabetes [29, 30]. In 
particular, one set of TGC trials using them was not particularly successful [31, 32]. 
They offer the tradeoff of sometimes significant added sensor noise with their far 
higher, automated sampling rate [28, 33]. However, these sensors and their 
algorithms are improving every year so the technology is in a state of constant 
evolution. Hence, their eventual effective use is potentially inevitable and will free 
clinicians to provide tighter control in the face of highly dynamic metabolic behaviour. 
 
This  paper uses data from the SPRINT TGC study [11]. It examines each of the 7 
cases of hypoglycemia that was not a function of sensor error. Conservative sensor 
noise based on reported data in the literature is added to model results fitted to the 
data to simulate the use of CGM. A novel integral-based algorithm with a median 
filter is used to develop a robust and readily generalised alarm approach and prove 
the concept in this in silico study. 
2.0 Subjects and Methods: 
 
2.1 Subjects: 
 
This research was conducted as a retrospective study using records from 7 patients 
admitted to the Christchurch Hospital ICU between 2005 and 2007. Patients were 
included if they had one or more severe hypoglycaemic episodes (BG < 40 mg/dL) 
while on the SPRINT glycaemic control protocol [11]. Patients were excluded if the 
hypoglycaemic episode appeared to be due to sensor failure [34] or were found to be 
due to a recording error. Details of the cohort are shown in Table 1. 
 
Table 1: Cohort details, presented as median [100% range] where applicable. APACHE II – 
Acute Physiological and Chronic Health Evaluation 2. ROD – Risk Of Death. 
 
N 7 
Male/Female 4/3 
25 APACHE II score 
[12-30] 
53 APACHE II ROD (%) 
[5-72] 
63 Age (yrs) 
[37-81] 
38 Hypoglycemic blood 
glucose level (mg/dL) [31-40] 
 
 
The requirement for patients in this study to be on the SPRINT protocol ensures they 
have regular, consistent and accurate records of blood glucose level (1-2 hourly), 
and insulin and nutrition administration [11]. The use of these patient records falls 
under existing ethics approval granted by the Upper South Regional Ethics 
Committee, New Zealand. 
 
2.2 Methods – CGM Noise Model: 
 
CGM sensor error consists of a bias due to calibration drift with a random, or quasi-
random noise superimposed on top. Calibration drift due to sensor degradation over 
time was not considered in this study as this is controlled by the specific calibration 
protocol used with the sensor. The random component of noise modeled in this study 
was assumed to be independent and normally distributed.   
 
This research used a single-Gaussian noise model. The model was derived to  
produce similar errors on a similar cohort to those reported by Goldberg et al in a 
2004 study of the Medtronic CGMS (Minimed-Medtronic, Northridge, CA) in a 
medical ICU [28]. In the study by Goldberg et al, the calibration of the CGM sensors 
was performed retrospectively with all the available data and at least 4 reference BG 
measurements per day [28], removing any bias. This report was used as it was 
critical care specific and reported a wide range of error statistics versus a reference 
measure. Goldberg et al reported errors for measurements in 5 BG ranges. The 
noise model was thus created to match the reported noise statistics over the same 5 
ranges. 
 
More specifically, it is a Gaussian distributed random error with a mean absolute 
percentage error (MAPE) of 12.8% and standard deviation (SD) of 10% on a cohort 
similar to Goldberg’s. However, the percentage error was greater for lower blood 
glucose levels here (MAPE 17.8%), given the relatively constant mean absolute 
difference (MAD) in mg/dL seen. Since, such lower measurements are more 
frequently encountered in this study involving tightly controlled patients on SPRINT, 
and which are limited to the time periods around hypoglycaemic episodes, the errors 
in MAPE are conservatively higher. However, these errors are also more relevant as 
they are specific to the hypoglycemia alarm situation studied here. 
 
2.3 Methods – In Silico CGM Measurements: 
 
Using a model derived from the clinically validated glucose-insulin model of Lin et al 
[35], and hospital records, a blood glucose profile was generated for each patient at 
5 minute intervals, based on their model-fitted time-varying insulin sensitivity. These 
profiles were generated in a data window starting 9 hours before the severe 
hypoglycemic event at a normoglycemic level and ending 4 hours after an actual 
measured hypoglycaemic event. Random noise was added to this ‘actual’ blood 
glucose profile using the single-Gaussian model, creating a sequence of virtual CGM 
sensor outputs. 
 
2.4 Methods –CGM Filtering: 
 
To simulate the real-time use of a CGM device, an algorithm was implemented in 
Matlab™ (The Mathworks, Natick, MA) to step through the sequence of virtual CGM 
readings and filter them without knowledge of ‘future’ values, as would be the case 
clinically. Thus, the clinical situation can be simulated for developing an alarm 
methodology. 
 
A combination median filter and least mean squares (LMS) curve fit was used to 
smooth the noisy virtual CGM sequence. Initially, a weighted median filter was 
applied to the prior 30 minutes noisy data, followed by a linear least squares fit over 
the previous hour median filtered data.  
 
The fundamental steps to implement the median filter at any given time t = x, are: 
 
1. Take current and 2 prior CGM readings (3 sample, 10 minute window) and find 
median value M3 
2. Take current and 6 prior CGM readings (7 sample, 30 minute window) and find 
median value M7 
3. Take average of M3 and M7 = MA 
4. Take current MA value and 12 prior MA values (1 hour window of median filtered 
values)  
5. Fit LMS 1st order polynomial line 
6. Output value at time t = x is the value of this fitted line at t = x 
 
This set of steps is based on well know median filtering [36] and LMS polynomial 
fitting methods. The multiple windows give an empirically designed trade-off between 
fast dynamics and response, and longer windows and smoother filtered outputs with 
lag [37].This approach is also less computationally expensive than integral based 
approaches or Kalman filtering [38-40]. 
  
2.5 Methods –Alarm Design: 
 
An algorithm was required to trigger an alarm when the filtered blood glucose 
sequence appeared to be heading towards a hypoglycaemic event. While better than 
the raw data, the filtered data was still too noisy to apply a simple set of conditions 
such as m measurements below a threshold BG value. Therefore, a windowed 
integral method (essentially an FIR filter [41]) was implemented using the filtered 
data. This approach is both simple and robust to noise.  
 
Specifically, the area between the BG curve and a specified level was calculated 
within a window of prior samples. When this integral became less than a pre-selected 
threshold value, an alarm was triggered, indicating an impending hypoglycaemic 
episode. Several combinations of these parameter values were simulated. Figure 1 
shows an example. 
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Figure 1: An example showing the blood glucose integral used to trigger a hypoglycaemic 
alarm. 
 
 
An alarm was considered false if the following conditions held: 
 
? There was more than 1 alarm for each actual hypoglycaemic episode per 
patient AND 
? For 2 clinical blood glucose measurements either side of the alarm, no value 
was less than or equal to 40 mg/dL. 
 
It should be noted that this use of prior knowledge of clinical BG measurements was 
only used after the filtering and processing to identify any false alarms, and would 
thus not be a part of a real-time implementation.  
 
2.6 Methods –Analysis: 
 
For analysis, the timing of this alarm was compared with the time that the episode 
was actually detected in the hospital. This value essentially measures the lead time 
to intervene and the minimisation of minor or moderate hypoglycemia. The number of 
false alarms was also recorded to ensure that the method was accurate. 
 
To get meaningful results with the random noise, this study used a Monte Carlo 
analysis approach. Each patient’s model-based, true BG profile was passed through 
the single-Gaussian random noise generator 100 times, creating 100 different virtual 
CGM sequences per patient. The results of these 700 trials with the filter and alarm 
algorithm were analysed using non-parametric statistics to determine overall cohort 
and per-patient results.  
 
Results were reported in terms of alarm lead time and number of false alarms for 
several analyses and thresholds. A simple glycemic threshold method is also shown 
for comparison. 
 
 
3.0 Results: 
 
3.1 Filter Results: 
 
The median and LMS based filter design resulted in a significant noise reduction. 
Specifically the MAPE on raw noisy virtual outputs was reduced from 17.4% (SD 
13%) to 9.3% (SD 7%) over the cohort. However, given relatively smaller numbers of 
hours (N = 91 hours over 7 patients) the distributions were not perfectly normal. 
Thus, the non-parametric filtering output was a reduction from a median APE of 
14.4% [IQR: 6.8 - 24.9]  to a median APE of 7.6% [IQR: 3.6 - 13.2]. Mean absolute 
differences (MAD) were 14.7 mg/dL and 7.7 mg/dL, respectively. All these values 
compare well with results reported in the literature [28, 39, 40]. 
 
3.2 Alarm Analysis Results: 
 
The primary result for this study was the time difference between an alarm triggered 
by the simulated CGM data and when a hypoglycaemic episode was detected by 
actual measurement. As a secondary result, the number of false alarms triggered is 
also reported as a measure of the alarm algorithm’s reliability. Table 2 shows results 
for the integral-based alarm for different window lengths and trigger threshold values. 
Negative time values indicate that and alarm was triggered before a hypoglycaemic 
event was measured. These results are counted over all 700 Monte Carlo simulation 
runs. 
 
 
Table 2: Early detection of hypoglycaemic episodes reported for the integral-based alarm 
algorithm with a range of parameter values. Data are median [IQR] for all 700 Monte Carlo 
runs (100 per patient). 
 
 
 
 
 
 
 
 
 
 
 
 
Integration window 
length (samples)
Integral threshold 
(mg.min/dL) 5 10 20 5 10 20 5 10 20
-65 -95 -145 -55 -85 -130 -35 -55 -120
[-110, -35] [-120, -55] [-180, -120] [-95, -30] [-120, -50] [-180, -115] [-73, -15] [-95, -25] [-160, -85]
-65 -90 -170 -60 -80 -150 -35 -55 -120
[-94, -33] [-118, -56] [-180, -124] [-83, -31] [-110, -47] [-180, -123] [-66, -16] [-88, -26] [-166, -101
58 64 78 55 62 75 52 55 72
[55, 60] [62, 66] [74, 79] [53, 57] [60, 64] [71, 77] [48, 54] [51, 60] [61, 75]
1 1 2 1 1 2 0 1
[0, 2] [0, 2] [1, 3] [0, 1] [0, 2] [1, 3] [0, 1] [0, 1] [1, 2]
13
Hypo detection time
cohort (min)
Hypo detection time
patient median (min)
BG level at alarm 
(mg/dL)
false alarms
5 7
]
1
 
Despite the sensor noise, there is a clear improvement in the time of detection of 
hypoglycaemic episodes using CGM sensors compared to standard clinical 
procedures measuring 1-2 hourly with, in this case, SPRINT. The degree of 
improvement depends on the design and parameters of the alarm algorithm 
presented. The reliability of the alarm, as measured by the number of false alarms 
decreases with increasing advanced detection time.  
 
As a comparison, Table 3 shows the results of using a simple glycemic level alarm 
algorithm. The alarm is triggered in this case by 3 consecutive CGM readings below 
the threshold BG value and a negative average gradient over those 3 points. It is 
obvious that the performance is significantly worse than the integral-based algorithm. 
False alarm values of -1 indicate that no alarms were triggered at all despite the 
hypoglycemic event occurring in each case. Thus, the results in this table show that 
for more than 75% of the time, with a threshold value of 50 mg/dL, no alarm was 
triggered despite the oncoming, glycemically near, hypoglycemic event. 
 
Table 3: Early detection of hypoglycaemic episodes reported for the simple glycemic 
threshold value-based alarm algorithm for all 700 Monte Carlo runs. Data are median [IQR]. A 
negative value in false alarms indicates that no alarm was triggered. 
 
Consecutive points 
below alarm threshold
Average gradient at 
threshold (mg/dL.min)
Alarm threshold 
(mg/dL) 50 60 70
-15 -40 -75
[-25, -5] [-75, -25] [-110, -45]
-10 -40 -75
[-26, -10] [-69, -25] [-105, -41]
44 50 55
[41, 46] [44, 53] [52, 62]
-1 -1 7
[-1, -1] [-1, 6] [-1, 13]
false alarms
3
< 0
Hypo detection time
cohort (min)
Hypo detection time
patient median (min)
BG level at alarm 
(mg/dL)
 
 
Figure 2 shows a typical example of filtered CGM data for one patient run plotted 
alongside the actual measured 1-2 hourly blood glucose values. The dark band and 
line show the median (line) and IQR (shaded band) of the CGM hypoglycemic event 
detection for the entire 100 Monte Carlo runs over this patient, for a window length of 
7 samples and integral threshold of 10 mg.min/dL. First, it is evident that even when 
filtered, the CGM data is still relatively noisy. This noise can cause false alarms and 
impact on the reliability of the method.  
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Figure 2: An indication of the early hypoglycaemic detection provided by CGM sensors for 
one patient showing the median [IQR] for detection over all 700 Monte Carlo runs. The 
measured data (circles) and one example of the filtered CGM data (line) are shown for 
context.  
 
Second, the range of hypoglycemia detection is still well in advance of the measured 
hypoglycemic event at 15 hours. The hypoglycemic value is 39 mg/dL and thus it 
may also be assumed that it likely occurred very near this time. The IQR of detection 
is 50-120 minutes before the event, which was preceded by a stable range of 
glycemia around 90 mg/dL for several hours. 
 
Figure 3 illustrates how false alarms can occur. The integral window length and 
threshold were 7 samples and 10 mg.min/dL, respectively. There were two false 
alarms recorded at 14.8 and 17.2 hours. Although the actual blood glucose 
measurements remain fairly constant, the noisy CGM data pulled the value of the 
integral below the threshold value, triggering an alarm. The actual alarm wasn’t 
triggered until 21.3 hours, 45 minutes before it was detected by clinical 
measurements. Hence, in this case, the actual event was detected and reliably 
alarmed but minor hypoglycemia at 15-18 hours (60-65 mg/dL) triggered false alarms 
in this particular Monte Carlo run. Other  Monte Carlo runs did not trigger false 
alarms. 
 
 
 
12 13 14 15 16 17 18 19 20 21 22 23
0
20
40
60
80
100
120
140
160
180
200
-50
-40
-30
-20
-10
0
10
20
30
40
50
 Time, t (hrs) 
Measured BG points 
Filtered CGM data 
Integral value 
Alarm threshold 
Real alarm 
False alarm 
 
B
lo
od
 G
lu
co
se
, B
G
, (
m
g/
dL
) 
 I
nt
eg
ra
l v
al
ue
 (m
g.
m
in
/d
L)
 
 
Figure 3: An illustration of false alarms triggered during a simulation 
 
 
4.0 Discussion: 
 
While CGMs are well studied in ambulatory type 1 diabetics [29, 30], there have 
been relatively few successful investigations of CGMs in critically ill in-patients [28].  
There are several important differences between critically ill patients and ambulatory 
type 1 diabetics, which may have an impact on the performance of the CGM device. 
Critically ill patients are generally insulin resistant [1-7] due to high levels of counter 
regulatory stress hormones and consequently hyperglycaemic without adequate 
control. Insulin resistance coupled with continuous feeding and sedation, limits the 
rate of change of blood glucose levels, preventing rapid changes that can occur with 
meals and exercise an possibly resulting in improved CGM performance compared to 
ambulatory individuals. On the other hand, peripheral oedema, a lack of dynamic 
circulation of the interstitial fluid due to the non-ambulatory state [42] may reduce 
performance.  
 
4.1 Performance: 
 
The results of this study show that using CGM sensors for early hypoglycaemic event 
detection in an ICU can be very effective. Depending on the design of the filter and 
alarm algorithm, reliably detecting hypoglycaemic events 1-2 hours before they would 
normally have been picked up is quite feasible, allowing very early intervention. Early 
detection and intervention may reduce or eliminate both the events themselves and 
thus any harm caused by these episodes.  
 
Filtering the raw CGM output with the median filter/LMS fit provides better results 
than using a more common FIR filter (results not shown). The raw, noisy CGM data 
had a MAPE of 17.4%, the median/LMS filter reduced this to 9.3% for this cohort. To 
provide a comparison with “standard” filtering methods, a 9th order low-pass FIR filter 
designed using the window method results in a MAPE of 13.7% which is much higher 
than this filtering approach for the same data. 
 
Using an integration-based algorithm to trigger the alarm is much more effective than 
a simple consecutive value-based or derivative-based methods. The residual noise, 
post-filtering is still enough to trigger multiple false alarms with a high threshold, or to 
prevent any alarms at all with a lower threshold when simply using the filtered BG 
values to trigger the alarm. Table 3 illustrates this point, particularly with an alarm 
threshold of 60 mg/dL. No alarms were triggered in more than 50% of the simulations 
with this threshold value, but in 25% of simulations up there were 6 or more false 
alarms triggered as the IQR 75th percentile is 6 in Table 3 for some cases. Derivative 
based algorithms were not considered in this study as they are known to be highly 
susceptible to noise whereas integrals filter noise much like a basic FIR or other 
digital filter. The integral-based algorithm is thus more robust to noise and therefore 
provides a much more reliable alarm. 
 
Sensor error due to bias has not been modeled in this research, as it is a calibration 
issue rather than strictly noise. However if present and positive (BG actually lower 
than measured), bias would reduce the lead time for hypo detection. If negative bias 
was present (BG actually higher than measured), the detection lead time would be 
improved, however the number of false positive detections may also increase. The 
potential presence of sensor bias therefore necessitates careful calibration of the 
device and tuning of the detection algorithm to ensure good performance. 
 
Tuning the integral algorithm to optimise the performance involves adjusting the 
window length and the alarm threshold parameters. There is a trade-off with integral 
window length, where long windows provide a more reliable alarm, but with less 
advance warning than shorter windows. With a long window, the integral takes longer 
to fall below the threshold once the blood glucose starts dropping. This trade-off also 
explains why a lower alarm threshold parameter is more reliable, but provides less 
warning than a higher value.  
 
Selecting the optimal values for window length and alarm threshold would ideally be 
done over a larger set of patients than used in this proof of concept analysis. This 
study has a number of limitations however, the method presented can be readily 
generalised to ICU populations. This performance would justify a pilot clinical trial, 
not only to validate the detection algorithm, but also the assumptions behind the 
simulated noise. 
 
4.2 Limitations – Clinical: 
 
The small number of patients in this study (7) may mean the results are not 
representative of the overall population behaviour. Repeating the study with a larger 
cohort would provide a more statistically powerful result. However, in the 
Christchurch ICU all patients receiving insulin are on the SPRINT glycaemic control 
protocol and therefore very unlikely to suffer a serious hypoglycaemic event (~4% of 
patients or less), making it difficult to recruit a large cohort. Data from a different 
study might alleviate this issue for in silico studies, or  a pilot clinical trial should be 
developed. 
 
A further limitation is that only hypoglycaemic episodes at or below 40 mg/dL were 
investigated in this research. The SPRINT protocol controls patients between 72 
mg/dL and 108 mg/dL [11, 25] without significant prejudice towards lower values in 
this range. Hence, examining a higher hypoglycaemic level (e.g. moderate 
hypoglycemia < 60 mg/dL) is infeasible as getting closer to the target band results in 
more false alarms. Uncontrolled or poorly controlled patients may permit the 
investigation of CGM hypoglycemic detection performance on less severe episodes.  
 
Finally, although the virtual patient simulation method is clinically well validated [25, 
34, 43-45], this in-silico study needs to be confirmed with clinical testing. The actual 
blood-glucose sequences used were model-based, derived from 1-2 hourly clinical 
measurements with added noise, not real CGM output data.  Testing and validation 
of the findings in a clinical setting, particularly the noise model and will confirm the 
results. 
 
4.3 Limitations – Signal Processing: 
 
Signal processing and noise model limitations of this study were that we only 
considered a conservative noise model, simple filtering methods and ignored 
calibration drift or bias. We assumed non-biased, random independent noise based 
on reported data.  
 
CGM sensor error consists of a bias due to calibration drift with a random, or quasi-
random noise superimposed on top. Calibration drift due to sensor degradation over 
time was not considered in this study. Without correction, calibration drift will show up 
as though the actual BG measurements were higher or lower in a relatively 
consistent manner as the sensor gain drifts [40]. This drift would cause the alarm to 
trigger early (possibly falsely) or late. However, such calibration drift is very much a 
function of the frequency and quality of calibration measurements which can likely be 
controlled more readily in a critical care setting. 
 
The random component of noise modeled in this study was assumed to be 
independent and normally distributed. The assumption of independent errors may not  
model the actual CGM sensor noise perfectly, but with no reported time-series data 
available in literature (to the authors' knowledge), a more comprehensive model was 
not possible.  
 
The Gaussian noise model employed was conservative (MAPE = 17.4% for this 
cohort) as it was based on data from a 2004 study [28] and there have been 
significant advances in emerging CGM sensor hardware and software since that 
time. Improved sensor noise characteristics combined with more advanced filtering 
techniques would result in a much cleaner CGM data stream and hence more 
reliable alarms. However, the higher noise levels used thus provide a conservative 
test of the approach. 
 
This study only investigated simple median/LMS and FIR filters. More advanced 
filtering techniques, such as adaptive filtering and Kalman filtering have been shown 
to produce very good results [39, 40]. Kalman filtering can also be used to correct for 
calibration drift [40], which was not studied in this case. However, it is difficult to 
compare performance here as all have used different data with different noise or 
error distributions from the sensors. 
 
 
4.4 Limitations – Analysis Method: 
 
It should be noted that this proof of concept study examined only  hypoglycemic 
events. Thus, there were no opportunities to examine “false positive” alarms. The 
false alarms here occurred significantly before, or in some cases after, the 
hypoglycemic event. The false alarms here are thus more representative of a lack of 
robustness.  
 
However, as seen in Figure 3, moderate hypoglycemia, which is corrected before the 
severe hypoglycemic event, can still trigger a false alarm if the thresholds are not 
perfectly optimised – an effort that may be nearly impossible given the variety of 
patient behaviours that can be encountered. That said, a trigger at this level is still 
clinically useful and definitely not spurious with regard to treating. Thus, another view 
of Figure 3 would be that these false alarms, if not frequent may be earlier precursors 
of hypoglycemic dynamics in the patients response to the intervention, which could 
potentially be used to moderate care. 
 
 
4.5 Summary: 
 
Finally, while these are significant limitations, this paper is focused on proof of 
concept for a novel integration based method of hypoglycemia detection. The primary 
goal was to develop a method for accurate, reliable alarms with good warning that 
account for realistic or greater sensor noise that was also readily generalisable to 
similar sensors. Thus, the larger noise used is a conservative test and application to 
cases with lesser noise will provide better results. The main comparison to other 
alarm methods should then be in terms of relative performance presented here. 
Overall, the good result with sub-optimal filtering and a conservative noise model 
only serves to show that the method is feasible and deserves further investigation. 
 
Finally, examining the SPRINT and prior pilot trial results, hypoglycemia could have 
been avoided without using CGM if measurements were made every 30 minutes 
(48/day). However, this rate potentially is invasive to the patient and far too 
burdensome for regular practice in a clinical ICU environment. Hence, CGM offers 
the opportunity to observe trends semi-invasively and reduce clinical burden, while 
also increasing potential safety by mitigating the tradeoff between the burden of more 
frequent measurement, and the safety and tight glycemic control outcomes that it can 
provide. In SPRINT, even 1-2 hourly measurements yielded only 10 events over 8 
patients (2%), a majority of which were due to clinical errors. So, the methods 
presented here are thus about reducing a potentially small number of events to zero 
as well as mitigating the clinical burden of frequent measurement. 
 
 
 
5.0 Conclusions: 
 
This paper has developed and analysed, in silico, a hypoglycemia alarm detection 
method for application with CGM sensors in critical care or, potentially, other hospital 
patients. While the results remain to be verified in a pilot clinical trial, the overall 
method appears robust and accurate to conservatively large sensor noise. The main 
conclusions and outcomes drawn include: 
 
• A median filter with LMS smoothing was presented and shown to be robust at 
removing significant sensor noise with minimal lag compared to standard FIR 
filters and similar to reported results for more advanced filters. 
• An integral based method was developed and seen to provide robust 
hypoglycemia detection with significant lead time before the event to enable 
intervention. The number of false alarms was very low and performance was 
better than the simple use of thresholds by using the integral approach. 
• The results presented justify a pilot clinical trial of the methods. 
 
Finally, the methods presented are readily generalisable to other hypoglycemic levels 
or control protocols. 
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